5. Jung HW, Kim HY, Kim JY, Cheon JE, Kim IO, Kim SK, et al. Correction: autonomic dysfunction is associated with increased cardiometabolic risk in patients with childhood-onset craniopharyngioma. Horm Metab Res 2020;52:e2.
6. Verhelst J, Mattsson AF, Luger A, Thunander M, Goth MI, Koltowska-Haggstrom M, et al. Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol 2011;165:881–9.
7. de Vile CJ, Grant DB, Hayward RD, Kendall BE, Neville BG, Stanhope R. Obesity in childhood craniopharyngioma: relation to post-operative hypothalamic damage shown by magnetic resonance imaging. J Clin Endocrinol Metab 1996;81:2734–7.
10. Holmer H, Ekman B, Björk J, Nordstöm CH, Popovic V, Siversson A, et al. Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy. Eur J Endocrinol 2009;161:671–9.
11. Kohno H, Ueyama N, Yanai S, Ukaji K, Honda S. Beneficial effect of growth hormone on atherogenic risk in children with growth hormone deficiency. J Pediatr 1995;126:953–5.
13. Feinberg MS, Scheinowitz M, Laron Z. Cardiac dimension and function in patients with childhood onset growth hormone deficiency, before and after growth hormone retreatment in adult age. Am Heart J 2003;145:549–53.
14. Gotherstrom G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson B, et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 2001;86:4657–65.
15. Attanasio AF, Shavrikova E, Blum WF, Cromer M, Child CJ, Paskova M, et al. Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. J Clin Endocrinol Metab 2004;89:4857–62.
16. Carroll PV, Drake WM, Maher KT, Metcalfe K, Shaw NJ, Dunger DB, et al. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. J Clin Endocrinol Metab 2004;89:3890–5.
19. Puget S, Garnett M, Wray A, Grill J, Habrand JL, Bodaert N, et al. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg 2007;106(1 Suppl):3–12.
21. World Health Organization. Western Pacific Region. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia. 2000.
22. Moon JS, Lee SY, Nam CM, Choi JM, Choe BK, Seo JW, et al. 2007 Korean National Growth Charts: review of developmental process and an outlook. Korean J Pediatr 2008;51:1–25.
23. Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes 2007;8:299–306.
24. Wijnen M, Olsson DS, van den Heuvel-Eibrink MM, Hammarstrand C, Janssen J, van der Lely AJ, et al. The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up. Eur J Endocrinol 2018;178:11–22.
26. Srinivasan S, Ogle GD, Garnett SP, Briody JN, Lee JW, Cowell CT. Features of the metabolic syndrome after childhood craniopharyngioma. J Clin Endocrinol Metab 2004;89:81–6.
29. De Vile CJ, Grant DB, Kendall BE, Neville BG, Stanhope R, Watk ins KE, et al. Management of childho o d craniopharyngioma: can the morbidity of radical surgery be predicted? J Neurosurg 1996;85:73–81.
33. Angelin B, Rudling M. Growth hormone and hepatic lipoprotein metabolism. Curr Opin Lipidol 1994;5:160–5.
34. Parini P, Angelin B, Lobie PE, Norstedt G, Rudling M. Growth hormone specifically stimulates the expression of low density lipoprotein receptors in human hepatoma cells. Endocrinology 1995;136:3767–73.
36. van der Klaauw AA, Romijn JA, Biermasz NR, Smit JW, van Doorn J, Dekkers OM, et al. Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. Eur J Endocrinol 2006;155:701–8.
37. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107–13.
38. Choi JH, Yoo HW. Reassessment of GH status and GH therapy in adults with childhood-onset GHD: transitional care from adolescence to adulthood. J Korean Soc Pediatr Endocrinol 2011;16:1–6.